International cooperation activities within JPIAMR aim to:
- build the critical mass needed to provide an effective response to the AMR challenge;
- coordinate global AMR research funding, and
- participate more effectively in agenda setting in international AMR policy and research policy fora.
Below you can find an overview of the current global landscape of international AMR initiatives and JPIAMR engagement and collaboration with them.
Cooperation with international funders
JPIAMR collaborates with AMR international funding organisations, including those listed below.
An overview of AMR science policy and funding can be found in this article: Research, Innovation, and Policy: An Alliance Combating Antimicrobial Resistance, Trends in Microbiology, April 2019.
“AMR Educational Activity – Joint Programming Committee”
JPIAMR participates in this action with Carb-X, Wellcome, GARDp, Novo Repair who sponsor sessions in key international events and co-branded joint activities such as in ECCMID or ASM. An example of the types of actions of this group can be seen here: External Webinars – REVIVE (gardp.org)
ICARS collaborates with JPIAMR through participation in joint calls supporting researchers in low and middle income countries (LMIC). ICARS works to develop partnerships with LMICs to advance the implementation of their National Action Plans (NAPs. More information on ICARS can be found here: ICARS – International Centre for Antimicrobial Resistance Solutions (icars-global.org)
Engagement with international organisations
JPIAMR works actively to engage with International Organisations on AMR. The following is a list of some of the organisations that JPIAMR engages with.
JPIAMR provided input on the AMR research policy section to the UN Interagency Coordination Group on Antimicrobial Resistance (IAGC) that provides recommendations on a global AMR governance to the UN Secretary-General.
World Health Organization
JPIAMR was involved in the WHO pre-clinical pipeline analysis as well as updating the clinical antibacterial pipeline analysis. It also provided input to the drafting of the selection criteria for products that would be funded through a potential new “WHO/EIB impact investment fund” to support late clinical development for antibacterials and diagnostics. JPIAMR is also taking part of the expert group on new fungal priority pathogen list.
The European Commission
JPIAMR works closely with the European Commission (EC). The EC is a non-voting member of JPIAMR through representatives of DG Research and Innovation. There is fluent dialogue in coordination of activities and calls. Ongoing conversations are held with the EC in regards to a new “One Health AMR European Partnership”. Read more on the support frpom the EC.
International policy engagement
JPIAMR has been highlighted as a key international initiative by different international organisations. Below are some of the documents that refer to JPIAMR:
- UN IACG report 2019
- G7 declaration 2017
- G20 Health Ministers declaration 2018
- The EU Council Conclusions on AMR 2019
- The European One Health Action Plan against AMR 2017
- Global AMR Action Plan 2015 (WHO)
Regional workshops across continents
JPIAMR has held several geographic workshops to develop “R&D International Cooperation for tackling the global AMR challenge”. Click on the workshop name to download the workshop report in pdf.
- JPIAMR Regional Workshop in Asia, Fostering knowledge on Clinical Epidemiology, AMR policy, Therapeutics and Diagnostics to combat AMR in Asia, 4-5 December 2019, Suwon, South Korea
- JPIAMR Regional Workshop in Eastern Europe, The role of a Joint Strategic Research and Innovation Agenda at global level for tackling AMR, 5-6 December 2019, Bucharest, Romania
- JPIAMR Regional Workshop in Latin America, Experiences and Areas of Interest for Strengthening Antimicrobial Resistance Networks, 5-7 June 2019, Buenos Aires, Argentina
- US-Europe Workshop, Translatlantic collaboration on Clinical trials related to antimicrobial resistance, 21-22 January 2016, Stockholm, Sweden
JPIAMR is member of the following Stakeholders Boards of different AMR international complementary initiatives:
- AMR R&D Global Hub
- IMI and its Steering Group of Infectious Diseases regarding the coordination and complementarity of funding programmes.
- EJP One Health
- SEDRIC Surveillance Network
- European Clinical Trial Network (ECRAID) initiative
- Transatlantic Task Force on AMR (TATFAR)
- EU Openscreen
- Value DX